FRI0184 Angiotensin-converting enzyme and anti-angiotensin-converting enzyme antibodies in systemic sclerosis

Abstract

After four perfusions (weeks 0, 2, 6, 10) clinical improvement (healing of skin necrosis, reduced dyspepsia and dyspnoe, increased general feeling, reduced VAS from 80 to 20, increased opening of the mouth, increased movement of the hands and fingers) permitted a slow reduction of the daily steroid dose. Objectives ./. Methods ./. Results ./. Conclusion This is a case with positive therapeutic onset of infliximab (remicade) in a case with systemic sclerosis.